Latest Insider Positions


Danziger Asaf is listed as an insider in the following companies: NVCR / NovoCure Limited Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Holdings

Security Title Post Shares
NVCR / NovoCure Chief Executive Officer, Director 410,124

Latest Transactions

Latest
Tran Date
Security Code Shares Post Shares Percent
Change
Share
Price
Tran
Value
Post
Value
Percent
Change
2018-02-22 NVCR / NovoCure M 53,334 410,124 14.95 21.55 1,149,348
2018-01-29 NVCR / NovoCure S -13,974 356,790 -3.77 24.0152 -335,588 8,568,383 -3.92
2018-01-25 NVCR / NovoCure S -6,456 370,764 -1.71 22.4349 -144,840 8,318,053 -1.74
2018-01-24 NVCR / NovoCure S -10,600 377,220 -2.73 22.1705 -235,007 8,363,156 -2.81
2018-01-23 NVCR / NovoCure S -10,248 387,820 -2.57 22.033 -225,794 8,544,838 -2.64
2018-01-16 NVCR / NovoCure S -14,900 398,068 -3.61 22.1983 -330,755 8,836,433 -3.74
2018-01-12 NVCR / NovoCure S -22,895 412,968 -5.25 22.0239 -504,237 9,095,166 -5.54
2018-01-11 NVCR / NovoCure S -313,525 435,863 -41.84 22.3507 -7,007,503 9,741,843 -71.93
2018-01-08 NVCR / NovoCure A 283 749,388 0.04 15.045 4,258
2017-11-06 NVCR / NovoCure S -6,919 749,105 -0.92 22.00 -152,218 16,480,310 -0.92
2017-11-03 NVCR / NovoCure S -2,300 756,024 -0.30 22.00 -50,600 16,632,528 -0.30
2017-11-01 NVCR / NovoCure S -15,716 758,324 -2.03 22.0075 -345,870 16,688,815 -2.07
2017-10-31 NVCR / NovoCure S -150 774,040 -0.02 22.00 -3,300 17,028,880 -0.02
2017-09-25 NVCR / NovoCure S -900 774,190 -0.12 22.05 -19,845 17,070,890 -0.12
2017-09-14 NVCR / NovoCure S -1,772 775,090 -0.23 22.00 -38,984 17,051,980 -0.23
2017-09-13 NVCR / NovoCure S -35,500 776,862 -4.37 22.0146 -781,518 17,102,306 -4.57
2017-07-14 NVCR / NovoCure M 354,780 812,362 77.53 0.38 134,816
2017-07-11 NVCR / NovoCure S -5,183 457,582 -1.12 20.19 -104,645 9,238,581 -1.13
2017-07-11 NVCR / NovoCure S -2,200 462,765 -0.47 19.40 -42,680 8,977,641 -0.48
2017-07-10 NVCR / NovoCure S -203,900 464,965 -30.48 18.077 -3,685,900 8,405,172 -43.85
2017-07-07 NVCR / NovoCure S -70,459 668,865 -9.53 18.034 -1,270,658 12,062,311 -10.53
2017-07-06 NVCR / NovoCure S -5,050 739,324 -0.68 18.088 -91,344 13,372,893 -0.68
2017-07-05 NVCR / NovoCure S -155,088 744,374 -17.24 18.144 -2,813,917 13,505,922 -20.83
2017-07-05 NVCR / NovoCure A 2,545 899,462 0.28 6.673 16,983
2017-06-19 NVCR / NovoCure S -124,720 896,917 -12.21 15.514 -1,934,906 13,914,770 -13.91
2017-06-16 NVCR / NovoCure S -9,212 1,021,637 -0.89 15.018 -138,346 15,342,944 -0.90
2017-06-15 NVCR / NovoCure S -33,245 1,030,849 -3.12 15.187 -504,892 15,655,504 -3.23
2017-06-14 NVCR / NovoCure S -5,402 1,064,094 -0.51 15.007 -81,068 15,968,859 -0.51
2017-06-13 NVCR / NovoCure S -88,700 1,069,496 -7.66 15.232 -1,351,078 16,290,563 -8.29
2017-06-12 NVCR / NovoCure S -5,100 1,158,196 -0.44 15.085 -76,934 17,471,387 -0.44
2017-06-09 NVCR / NovoCure S -175,501 1,163,296 -13.11 15.128 -2,654,979 17,598,342 -15.09
2017-02-27 NVCR / NovoCure M 342,954 1,338,797 34.44 0.17 58,302
2017-01-06 NVCR / NovoCure A 3,156 995,843 0.32 6.673 21,060
2016-04-13 NVCR / NovoCure M 59,130 992,687 6.33 0.17 10,052
2016-03-03 NVCR / NovoCure P 10,000 933,557 1.08 15.00 150,000 14,003,355 1.07
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)

Peers of Danziger Asaf include the following: Ambrogi Michael J., Burkoth William T., DOYLE WILLIAM F, FUTRELL STEVE, GRANOFF MICHAEL D, GROENHUYSEN WILHELMUS CM, JANIS FRANCES, Kirson Eilon D., LAVIGNE LOUIS J JR, LEUNG GABRIEL, Langloss Timothy J., Longsworth Todd Christopher, MYLOD ROBERT J JR, Madden Martin J., Melnyk Peter M., PHILLIPS CHARLES G III, Palti Yoram, Perlhagen Gert L., Pomona Associates VII, L.P., Pomona Capital VII Fund Investors, L.P., Pomona Capital VII, L.P., Pomona G.P. Holdings LLC, Pomona Secondary Associates VII LLC, VERNON W ANTHONY, Volati Ltd, WFD Ventures Fund II, L.P., Wyss Hansjoerg, . Peers are determined by cross-linking the filings of Danziger Asaf with insider filings of others at the same companies.

Related News Stories

3 Young Biotechs Positioned To Upend Medicine

2018-05-17 seekingalpha
NovoCure is developing a fourth modality of cancer treatment that could be, and is beginning to be, used in supplementation with chemotherapy, radiation, and surgery. (3-0)

Lucky Seven: Immune Design Takes Off, Institutions Place Bets On Viking Therapeutics

2018-05-16 seekingalpha
The Lucky Seven is a swing-trading biotechnology portfolio of seven stocks listed in a way to reflect top picks and risk tolerance. The first three picks are the top picks (in no particular order). Risks are increased the further away a stock sits from #4 (the least risky stock). (65-2)

Lucky Seven: Omeros Pops, Exelixis Drops On Phase 3 Flop

2018-05-12 seekingalpha
Exelixis, in collaboration with Roche, failed a phase 3 trial. The market was very punishing. Is Exelixis still worth holding? (66-1)

4 Specialty Pharma Stocks That Deutsche Bank Likes for the Rest of 2018

2018-05-10 247wallst
While large cap pharmaceutical stocks have had a very solid year despite the rumbling by the administration over drug pricing, many smaller specialty pharmaceuticals have lagged. Despite that underperformance, some outstanding earnings and, in some cases, even better forward guidance could make some of these companies a best play for the rest of the year. (243-4)

Lucky Seven: Omeros Moves, Array Biopharma May Be Next

2018-05-08 seekingalpha
Global Blood Therapeutics posts 1Q earnings and provides update. Given the likelihood of a significant catalyst within a few weeks, we are moving its position to reflect greater risk. (338-2)